Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — J.P. Morgan Healthcare Conference 2021
70 slides from Therapeuticsmd's conference presentation, January 2021
Slide 1: Building the Premier Women's Health Company
Building the Premier Women’s Health Company January 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or the “Company”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statemen
Slide 3: Company Overview
Company Overview TherapeuticsMD ¥ Imvexxy estradiol vagin! inserts) Annoverar ~~ ma Seg e acetal i ——— Bi) UVA isis Cstraciol and progesterone capsules
Slide 4: Broad Product Portfolio Across the Woman's Health Life Cycle
Broad Product Portfolio Across the Woman’s Health Life Cycle Prenatal Vitamins CONTRACEPTION/ DYSPAREUNIA PRENATAL FAMILY PLANNING - VASOMOTOR (Vulvar & Vaginal CONTRACEPTION CARE SYMPTOMS PERIMENOPAUSE Atrophy) REPRODUCTIVE HEALTH MENOPAUSE MANAGEMENT 4
Slide 5: Transitioned from R&D to Commercial Execution Following Product Launches
Transitioned from R&D to Commercial Execution Following Product Launches EBITDA Breakeven Update § Company expects EBITDA improvement throughout 2021 First Half 2022E § Assuming a significant COVID impact in 1H Projected Quarterly 2021, projected quarterly EBITDA break-even EBITDA Breakeven 2022 pot
Slide 6: Updates for 2021
Updates for 2021 § Remain on track to meet Q4 2020 minimum net revenue covenant of $20M § Renegotiated minimum net revenue covenants for Q1 and Q2 2021 to $18M and $22M, respectively, which are based off of our COVID adjusted forecast § Continue to work with Sixth Street Partners to reset the covena
Slide 7: Recent Increase in M&A Activity in Women's Health by Large Cap Companies
Recent Increase in M&A Activity in Women’s Health by Large Cap Companies Six Recent Deals in the Women’s Health Space; five in the Last 18 Months Apr-17 Jun-19 Jan-20 Feb-20 Aug-20 Dec-20 Exclusive Acquisition Acquisition License Spin-off Acquisition Collaboration Agreement Note: All trademarks are
Slide 8: Our Three Growth Products
Our Three Growth Products TherapeuticsMD ¥ Imvexxy estradiol vagin! inserts) 4 q+ 10 meg ——— Bi) UVA isis Cstraciol and progesterone capsules
Slide 9: 2021 Commercial Priorities Aligned with Product Opportunities
2021 Commercial Priorities Aligned with Product Opportunities § ANNOVERA is positioned as the lead product with the sales force and receives the majority of commercial funding – Effective Jan 1st, gained first preferred contract with a PBM that covers ~20% of commercial lives – Approximately 250,000
Slide 10: ANNOVERA: Unique Opportunity to Create a New Segment within Birth Control
ANNOVERA: Unique Opportunity to Create a New Segment within Birth Control 10
Slide 11: 2021 ANNOVERA Projected Volume Contribution per Channel
JULY 2021 ANNOVERA Projected Volume Contribution per Channel ANNOVERA Projected Volume Growth Contribution (Y/Y) 70000 8,000 – 12,000 57,000 – 76,000 60000 5,000 – 6,000 30,000 – 43,000 50000 40000 30000 20000 14,000 – 15,000 10000 0 2020 Projected Volume TXMD Marketing, Sales, Refills Other Channel
Slide 12: 2021 ANNOVERA Projected Volume Build for Sales, Marketing and PBM Formulary
JULY 2021 ANNOVERA Projected Volume Build for Sales, Marketing and PBM Formulary ANNOVERA Projected Volume Growth Contribution (Y/Y) 70000 8,000 – 12,000 57,000 – 76,000 60000 5,000 – 6,000 30,000 – 43,000 50000 40000 30000 20000 14,000 – 15,000 10000 0 2020 Projected Volume TXMD Marketing, Sales, R
Slide 13: 2021 ANNOVERA Projected Volume Build Reflects Growing Writers and Rx Per Writer
2021 ANNOVERA Projected Volume Build Reflects Growing Writers and Rx Per Writer JULY § Champions and Loyalists growth driven by sales force § 2021 volume goal equivalent to ~1.5 champions per sales territory across the US § Dabblers and Trialists growth driven by sales force and white space marketin
Slide 14: 2021 ANNOVERA Projected Volume Build Reflects Growing Writers and Rx Per Writer
2021 ANNOVERA Projected Volume Build Reflects Growing Writers and Rx Per Writer JULY Avg Monthly Writers of ANNOVERA 4,000 ~3,700 Expect COVID 3,500 impact through 2Q ~3,300 3,000 2,500 ~2,100 2,000 ~1,600 1,500 ~1,200 1,000 ~800 500 ~200 ~170 - 1Q20 2Q20 3Q20 4Q20 E 1Q21 E 2Q21 E 3Q21 E 4Q21 E Avg
Slide 15: Sales Force Ability to Connect with Prescribers Significantly Down from Pre-COVID Levels
Sales Force Ability to Connect with Prescribers Significantly Down from Pre-COVID Levels Trend of Salesforce Reach & Frequency from Baseline Average Reach to Targets Average Frequency to Targets 5% 3% 0% 0% -5% Baseline -2% (4Q19) -15% -19% -19% -25% -23% -35% -45% -44% -49% -48% -55% Baseline 4th Q
Slide 16: Successful Marketing Programs during COVID Highlight 2021 Omni-Channel Plan
Successful Marketing Programs during COVID Highlight 2021 Omni-Channel Plan Media Channels - Advertising “Individualized” Content Print & Office Materials • Social/Display – • Direct Mail (quarterly) • Office Education Tools – Branded/nonbranded demo ring, anatomical model, • Emails with updated mes
Slide 17: Successful Programs During COVID Include Virtual Medical Support
Successful Programs During COVID Include Virtual Medical Support • Over 100 Programs conducted in the 4th quarter Fireside Chats • Planned to run throughout 2021 • Conducted over 55 speaker programs with 560 attendees • Generated over 470 attendees at the NPWH ANNOVERA Product Medical Education Thea
Slide 18: Consumer Awareness and Education through Digital and Social Outlets Efforts Are Key to Success
Consumer Awareness and Education through Digital and Social Outlets Efforts Are Key to Success § 60% of women in this category know the birth control method they want before seeing their Healthcare Professional § Market is moving to long-lasting contraceptives at a ~15% 8-year CAGR(1) § ~47% patient
Slide 19: 2021 ANNOVERA Consumer Plans - NEW Channels Overview
2021 ANNOVERA Consumer Plans - NEW Channels Overview Expanding into Broadening Reach with Custom Sponsorships - CTV Snapchat PopSugar and Other Platforms Channel Objective: Channel Objective: Channel Objective: • Increase awareness of ANNOVERA • Build brand awareness among • Increase awareness of an
Slide 20: 2021 PR Campaign - "Just Say Vagina"
2021 PR Campaign - “Just Say Vagina” NATIONAL SPOKESPERSON ON PRODUCT: COMEDIAN - WHITNEY CUMMINGS JUSTSAYVAGINA.COM NATIONAL MEDIA DAY # 1 D E C 1 5 TH 2 0 2 0 NATIONAL MEDIA DAY #2 Q2 SAMPLE TARGETS SOCIAL MEDIA CONTENT SERIES WHITNEY CUMMINGS, ANNOVERA CHANNELS KOL SPOKESPEOPLE STAKEHOLDER LETTER
Slide 21: 2021 ANNOVERA – PBM Contribution Projected to Contribute to Growth
2021 ANNOVERA – PBM Contribution Projected to Contribute to Growth Gained preferred coverage with one of the top pharmaceutical benefit managers (PBM) with ~20% of commercial lives effective Jan 1st: § For the contraceptive class, ANNOVERA will be the preferred branded contraceptive vaginal ring age
Slide 22: 2021 ANNOVERA Projected Volume Refill Contribution to Growth
JULY 2021 ANNOVERA Projected Volume Refill Contribution to Growth ANNOVERA Projected Volume Growth Contribution (Y/Y) 70000 8,000 – 12,000 57,000 – 76,000 60000 5,000 – 6,000 30,000 – 43,000 50000 40000 § Current refill rate is ~66%(1) 30000 § Projection assumes a refill rate of 20000 only 35% provi
Slide 23: ANNOVERA Growth Catalyst: High Future Refill Rate
ANNOVERA Growth Catalyst: High Future Refill Rate Strong approval rate from current and previous users 1,036 women: Phase 3 acceptability study(1) § After 1 year of use: Women currently on 75% of the women indicated that they 85% of the women indicated that prescription contraception, have stayed on
Slide 24: ANNOVERA Refills: Illustrative Power of Increased Refill Rates
ANNOVERA Refills: Illustrative Power of Increased Refill Rates Illustrative ANNOVERA Net Revenue Opportunity at Year 5 Focus on refills is a Key Assumptions for Model Below TherapeuticsMD core competency Assumes consistent 100,000 patients start on ANNOVERA each year (1-5 year) Net Revenue Per Unit
Slide 25: 2021 ANNOVERA Projected Volume Build from Other Distribution Channels
JULY 2021 ANNOVERA Projected Volume Build from Other Distribution Channels ANNOVERA Projected Volume Growth Contribution (Y/Y) 70000 8,000 – 12,000 57,000 – 76,000 60000 5,000 – 6,000 30,000 – 43,000 50000 40000 30000 20000 14,000 – 15,000 10000 0 2020 Projected Volume TXMD Marketing, Sales, Refills
Slide 26: Top Distributors in Key Channels
Top Distributors in Key Channels Other Distribution Channels Supplement TherapeuticsMD Sales Force ~135 Reps and Managers Delivering Our Current ANNOVERA Access and Volume 18.8M women on birth control annually Telemedicine Platforms Medicaid Market US Military Market MBG- Puerto Rico Large/Growing S
Slide 27: Six Birth Control Telehealth Providers Live
Six Birth Control Telehealth Providers Live § Emerging digital marketing and e-commerce platforms reaching millions of women each year § Over 75,000 units of NuvaRing dispensed in 2019 ANNOVERA is included on 6 telehealth platforms: All trademarks are the property of their respective owners. 27
Slide 28: Afaxys Overview – Significant Public Health and Contraceptive Experience
Afaxys Overview – Significant Public Health and Contraceptive Experience § #1 Provider of oral & emergency contraceptives to U.S. public health and university clinics § 10+ Years of providing reliable and affordable access to contraception § 8,000 Clinics and other public healthcare providers servic
Slide 29: Afaxys Highlights
Afaxys Highlights Afaxys launching ANNOVERA into the Medicaid market: ~15% of the overall birth control market § Medicaid market represents a significant revenue opportunity with ~15% of the Medicaid overall birth control market § 38 states cover ANNOVERA with Unrestricted Medicaid Fee for Service A
Slide 30: WSI: A Leader in Contraceptive Sales in the Military
WSI: A Leader in Contraceptive Sales in the Military WSI has significant experience working in the Federal Government Healthcare Systems WSI Previously launched NuvaRing into the military 92 Military bases § Our goal is to have ANNOVERA in all major military treatment facilities that provide contrac
Slide 31: Why is ANNOVERA a Unique Solution for the Military?
Why is ANNOVERA a Unique Solution for the Military? § Women in the military are actively on missions in the United States and across the world § Taking a daily pill while out in the field is not easy to do or remember § ANNOVERA, with one ring in a small case, is easy to utilize wherever these women
Slide 32: ANNOVERA Projected GTN Reflects Full Payer Coverage Starting in 2021
ANNOVERA Projected GTN Reflects Full Payer Coverage Starting in 2021 JULY WAC Price: ~$2,000 JULY WAC Price: $2,090 100% § Increased overall discounts/rebates reflect 90% increased preferred PBM coverage and 80% 32.50% expanded access in Public Health channels 45.50% § Net price assumes increased sa
Slide 33: IMVEXXY: Fastest Growing Branded Product in VVA Category
IMVEXXY: Fastest Growing Branded Product in VVA Category 33
Slide 34: IMVEXXY is "Redefining Relief"
IMVEXXY is “Redefining Relief” A highly effective patient experience supported by strong clinical attributes § Description/Indication § Small, digitally inserted, softgel vaginal insert that dissolves completely § Indicated for moderate to severe dyspareunia § Primary Benefit § Efficacy demonstrated
Slide 35: 2021 IMVEXXY Strategic Initiatives
2021 IMVEXXY Strategic Initiatives Increase Volumes and Market Share through PBM § Effective January 1st, only branded product covered at preferred status at top PBM (~20% of commercial lives) – Premarin® Cream, Osphena ®, Intrarosa ® and Estring ® brands are all excluded and only IMVEXXY will be co
Slide 36: 2021 IMVEXXY Strategic Initiatives
2021 IMVEXXY Strategic Initiatives TXMD Realizing Higher Net Pricing § Effective January 1st, cash pay program and high-deductible patients co-pay increased from $50 to $75 – Significant improvement in GTN anticipated – Expected increase in revenue due to higher net pricing should offset the effect
Slide 37: 2021 IMVEXXY Projected Volume Contributions per Channel
2021 IMVEXXY Projected Volume Contributions per Channel IMVEXXY Projected Volume Growth Contribution (Y/Y) 700000 560,000 – 570,000 (70,000) – (100,000) 75,000 – 130,000 535,000 – 600,000(1) 600000 500000 400000 300000 200000 100000 0 2020 Projected Volume Co-Pay Impact TXMD Sales & Marketing, 2021
Slide 38: 2021 IMVEXXY Projected Volume Build from Pricing Considerations
2021 IMVEXXY Projected Volume Build from Pricing Considerations JULY IMVEXXY Projected Volume Growth Contribution (Y/Y) 700000 560,000 – 570,000 (70,000) – (100,000) 75,000 – 130,000 535,000 – 600,000(1) 600000 500000 400000 300000 200000 100000 0 2020 Projected Volume Co-Pay Impact TXMD Sales & Mar
Slide 39: Quarterly Expected IMVEXXY Net Price Build Shows Significant Improvement in 2021
Quarterly Expected IMVEXXY Net Price Build Shows Significant Improvement in 2021 $75 $70-$73 Jan 1st Cash Pay $70 changed to $75 $65 $60-$65 2020 Projected Annual Blended 2021 Projected Annual Blended $60 Net Price Range: Net Price Range: $55 ~$46-$48 $52-$56 $65-$70 $51 $50 $45 $44 $41 $40 1Q20 2Q2
Slide 40: 2021 IMVEXXY Projected Volume Build for Sales, Marketing and PBM Formulary
2021 IMVEXXY Projected Volume Build for Sales, Marketing and PBM Formulary JULY IMVEXXY Projected Volume Growth Contribution (Y/Y) 700000 560,000 – 570,000 (70,000) – (100,000) 75,000 – 130,000 535,000 – 600,000(1) 600000 500000 400000 300000 200000 100000 0 2020 Projected Volume Co-Pay Impact TXMD
Slide 41: Reaching IMVEXXY Target Universe Through Field Force Visits and Multi-Channel Communications
Reaching IMVEXXY Target Universe Through Field Force Visits Strongly Supplemented by Multi-Channel Communications Marketing Targets: ALL TARGETS 20,000 Comprehensive Multichannel Approach FIELD FORCE TARGETS Field Targets: • Focused targeting 11,000 • Right mix of calls and samples have a positive i
Slide 42: 2021 is Our Year to Inspire and Drive Action with an Ownable and Differentiated Campaign
2021 is Our Year to Inspire and Drive Action with an Ownable and Differentiated Campaign for IMVEXXY Photomatic YOU TUBE Quant (% Based on all Respondents) 150 = 100% START VIDEO (1s +) Test and Learn with MOA Video (2 Minutes Long) Audio and video cannot be skipped for 5 seconds WATCHING AT 8 SEC C
Slide 43: Adherence is an Important Pillar to Keep Our Patient Engaged and Supported
Adherence is an Important Pillar to Keep Our Patient Engaged and 2 Supported to Stay on IMVEXXY Bond Her to IMVEXXY Via CRM Program 2020 Adherence Results § Adherence emails to patients § Focus on fills for IMVEXXY allows for via website opt-in for continued revenue growth continued engagement § Ave
Slide 44: IMVEXXY Market Growth Potential from PBM Preferred Contract
IMVEXXY Market Growth Potential from PBM Preferred Contract Gained preferred coverage with one of the top pharmaceutical benefit managers (PBM) with ~20% of commercial lives effective Jan 1st: § For the VVA class, IMVEXXY will be the only branded agent on formulary § Premarin Cream®, Intrarosa®, Osp
Slide 45: PBM Preferred Status a Significant Opportunity for IMVEXXY
PBM Preferred Status a Significant Opportunity for IMVEXXY § In 2019 across all of this PBM’s plans, there were 540,000 total VVA prescriptions, with 260,000 branded prescriptions § IMVEXXY is now the only branded product covered for the VVA class § 4 brands now blocked (Premarin® Cream, Intrarosa®,
Slide 46: Significant IMVEXXY GTN Improvement Projected Starting in 2021
Significant IMVEXXY GTN Improvement Projected Starting in 2021 WAC Price: ~$206 WAC Price: ~$227 JULY § Decreased patient co-pay assistance for 100% non-covered cash patients anticipated to 90% drive significant improvement in IMVEXXY GTN, offset by slightly higher payer rebates 80% 70% 68.40% 60% 7
Slide 47: VVA Market Opportunity Based on IMVEXXY Net Price ~$80
VVA Market Opportunity Based on IMVEXXY Net Price ~$80 TRx Addressable TRx (Monthly)* (including 60/90-day supplies as a single unit) Creams converted to monthly supply VVA Market Volume 2019 5,269,549 10,113,133 Net Revenue Per Unit Total Net Revenue ($M) Total Net Revenue ($M) $75 $395 $758 $80 $4
Slide 48: BIJUVA: First and Only FDA-Approved Bio-Identical Solution in VMS Market
BIJUVA: First and Only FDA-Approved Bio-Identical Solution in VMS Market 48
Slide 49: BIJUVA Fills a Significant Unmet Need for an FDA Approved Combination Bio-Identical Hormone Therapy
BIJUVA Fills a Significant Unmet Need for an FDA Approved Combination Bio-Identical Hormone Therapy § 2002 Women’s Health Initiative (WHI) study showed that the long-term use of certain synthetic hormones (a combination of medroxyprogesterone acetate and conjugated equine estrogens) increased the ri
Slide 50: BIJUVA is Indicated in a Woman with a Uterus for Treatment of Moderate to Severe VMS
BIJUVA is Indicated in a Woman with a Uterus for the Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause K E Y C L I N I C A L AT T R I B U T E S § First and only bio-identical combination of estradiol to reduce moderate to severe hot flashes combined with progesterone to help reduce
Slide 51: BIJUVA Targets a Multi-Billion Dollar Market in the US
BIJUVA Targets a Multi-Billion Dollar Market in the US FDA-APPROVED NOT FDA-APPROVED Combination Separate Compounded Synthetic Bio-identical Bio-identical Estrogens + Progestins(1) Estradiol & Progesterone Estradiol + Progesterone 12M – 18M annual prescriptions ~2M annual prescriptions(2) ~6M annual
Slide 52: Bio-Ignite Program
Bio-Ignite Program § Partnership program with compounding community § Distribution of TherapeuticsMD product portfolio § Channel largely ignored by pharmaceutical companies § Provides connection of community pharmacy to high writing E+P prescribers 52
Slide 53: The Bio-Ignite Partnerships are an Anchor for Future Growth
The Bio-Ignite Partnerships are an Anchor for Future Growth 70+ locations added since March 2019 Anticipated BIJUVA Usage Compounding pharmacists report that they would recommend BIJUVA for about 1/3 of the patients 300 32% ~270 31% 250 31% 200 30% ~160 150 29% 28% 100 28% 50 27% 0 26% # of location
Slide 54: NASEM Report
NASEM Report National Academies of Science, Engineering and Medicine (NASEM) § Report commissioned by FDA and published on July 1, 2020 to gain independent analysis of the safety and public health risk related to compounded bio-identical hormone therapy (cBHRT) § NASEM recommendations for stronger r
Slide 55: BIJUVA Market Opportunity Based on Long-Term Net Price Range
BIJUVA Market Opportunity Based on Long-Term Net Price Range VMS Market Analysis (2019) FDA-Approved Compounded Total TRx 7,187,700 8,000,000 15,187,700 Net Revenue Per Unit Total Net Revenue ($M) Total Net Revenue ($M) Total Net Revenue ($M) $75 $539 $600 $1,139 $80 $575 $640 $1,215 $85 $611 $680 $
Slide 56: Strong, Long-Term Patent Protection Across All Three Products
Strong, Long-Term Patent Protection Across All Three Products TODAY 2020 2032 2033 2039 // BIJUVA Patent Summary IMVEXXY Patent Summary ANNOVERA Patent Summary Patented claims cover the product and Patented claims cover the product and Patented claims cover the labeled the labeled indication the lab
Slide 57: Key Messages 2021 and Beyond
Key Messages 2021 and Beyond § Our focus for 2021 is to execute our commercial plan to drive outsized growth § Renegotiated minimum net revenue covenants for Q1 and Q2 2021 to $18M and $22M, respectively, which are based off of our COVID adjusted forecast § Continue to work with Sixth Street Partner
Slide 58: Appendix
Appendix TherapeuticsMD ¥ Imvexxy estradiol vagin! inserts) 4 q+ 10 meg ——— Bi) UVA isis Cstraciol and progesterone capsules 58
Slide 59: The Need for ANNOVERA
TherapeuticsMD” 2 : For Her: For Life. The Need for ANNOVERA
Slide 60: Prescription Birth Control Market
Prescription Birth Control Market Contraception Choice of Women Age 15-50 % of Women Using Prescription Contraception by Method (72 Million) 18.8 Million Women Patch 1% Ring Non- 4% 3 month prescription Prescription Injectable contraception 8% 14% Contraception 26% Implant Breakout of 26% on 9% Pres
Slide 61: Use of IUD Continues to Increase
Use of IUD Continues to Increase Status of Contraception Use Amoung Women 15-49 45.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% 2013 2017 2019 Not Using Contraception 38.3% 35.1% 34.7% Sterilization 20.6% 24.5% 23.7% Non-prescription Contraception 13.5% 14.3% 14.1% Oral Contraception 16.0%
Slide 62: Why is the IUD Market Vulnerable to Change?
Why is the IUD Market Vulnerable to Change? § Long-acting contraception is the first line recommendation from the CDC and medical societies(1), (2) ‒ The Affordable Care Act allowed for expanded access and affordability to LARC methods which were previously unaffordable for many women ‒ Medical Soci
Slide 63: The Developer of the Most Successful LARCs Understands a Large Section of the Market
The Developer of the Most Successful LARCs Understands a Large Section of the Market does not have a Long-Acting Solution EVERYONE can use Developer of all the original long-acting, reversible contraceptives and top selling products in the US and Worldwide § Over 150 million women worldwide are usin
Slide 64: The Population Council Developed ANNOVERA as a Long-Lasting Solution
The Population Council Developed ANNOVERA as a Long-Lasting Solution for all Patients and Providers § TXMD is looking to create a new market segment in the contraceptive market § The market void that exists today demands a long-acting Birth Control Product that ALL doctors can prescribe, and all Wom
Slide 65: Development led to a Differentiated Product that can create a new segment in Birth Control
Development led to a Differentiated Product that can create a new segment in Birth Control Primary Benefits: § Only FDA-approved long-lasting reversible birth control that does not require a procedure or repeat visit ‒ Empowers women to be in control of their fertility and menstruation ‒ Inserted fo
Slide 66: Segesterone Acetate – the Only Progestin Derived from Progesterone
Segesterone Acetate – the Only Progestin in Combination Hormonal Contraceptives Derived from Progesterone Derived from Derived from Progesterone Testosterone Progesterone Derived ü Testosterone Derived • Norethindrone Segesterone Acetate • Levonorgestrel/Norgestrel • Desogestrel/Etonogestrel • Norge
Slide 67: Real-World Evidence of ANNOVERA Market Share Gains from All Products
Real-World Evidence of ANNOVERA Market Share Gains from All Products Source; Symphony Prescriber level data supplement with VPS and copay card data vs competition based on Symphony Prescriber level data. 67
Slide 68: Anticipated Mix of ANNOVERA Patients Based on Survey and Real-World Data
Anticipated Mix of ANNOVERA Patients Based on Survey and Real-World Data § IUDs = ~21% • 20+% of IUD users that remove the IUD due to side effects § Implants = ~10% • 20+% of implant users that remove due to side effects § NuvaRing (single month ring) Users = ~20% • 30-40% market share of current Nu
Slide 69: ANNOVERA Patient Types
ANNOVERA Patient Types § A single contraceptive product for most patient and prescriber types – Benefits for the diversity of women – supports patient preference – Amenable to women of all ages and demographics – Available to all prescribers – no special training, equipment, or inventory § Immediate
Slide 70: Prescription Trends Continue to Increase Month Over Month
Prescription Trends Continue to Increase Month Over Month 2500 Full Consumer Launch 2,090 2,100 § ~17,000 TRx by ~5,000 2000 1,880 1,850 writers, since launch COVID 1,750 through December 2020 Response Plan 1500 NSM Field 1,170 1,153 Relaunch COVID 966 Impact 1000 Soft Launch 724 671 670 574 500 447
TherapeuticsMD — J.P. Morgan Healthcare Conference 2021 on 6ix